Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1

Conditions

Neurofibroma, Plexiform 3Neurofibromatosis 1 2Lung Neoplasms 2Carcinoma, Non-Small-Cell Lung 2Breast Neoplasms 2Triple Negative Breast Neoplasms 1To Evaluate the Efficacy of Fruquintinib and Pirfenidone in Combination With Anti-PD-1 Antibody in Colorectal Carcinoma 1Squamous Cell Carcinoma of Head and Neck 1Recurrence 1Radiation Fibrosis Syndrome 1Precancerous Conditions 1Pneumonia 1Neurofibromatoses 1Nerve Sheath Neoplasms 1Neoplasms 1Myofibroma 1Lymphedema 1Leiomyoma 1Colorectal Neoplasms 1Acute Lung Injury 1

Interventions

Cyclophosphamide 153Dexamethasone 141Rituximab 85fludarabine 79Lenalidomide 72Cytarabine 70Bortezomib 64fludarabine phosphate 63Gemcitabine 62venetoclax 54Etoposide 53pomalidomide 52pembrolizumab 52Paclitaxel 48Cisplatin 48Carboplatin 48Peripheral Blood Stem Cell Transplantation 47Filgrastim 40Radiotherapy 39Busulfan 37Calcium Dobesilate 36Methotrexate 34Melphalan 34Bevacizumab 33carfilzomib 32Cyclosporine 32Azacitidine 32Mycophenolic Acid 30Vincristine 29Bendamustine Hydrochloride 29

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Recurrence × pirfenidone × Clear all
NCT04467723 2026-01-28

Combination of Atezolizumab and Pirfenidone in Second-line and Beyond NSCLC

University of Kansas Medical Center

Phase 1/2 Recruiting
25 enrolled
Thoracic

Carcinoma, Non-Small-Cell Lung, Recurrence

Data powered by HemOnc (CC BY 4.0) Colophon âš¡